American Portfolios Advisors Nektar Therapeutics Transaction History

American Portfolios Advisors

$2.36 Trillion
Q3 2022

A detailed history of American Portfolios Advisors transactions in Nektar Therapeutics stock. As of the latest transaction made, American Portfolios Advisors holds 230 shares of NKTR stock, worth $299. This represents 0.0% of its overall portfolio holdings.

Number of Shares

230

Holding current value

$299

% of portfolio

0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Mar 17, 2023	BUY	$3.04 - $5.14 $699 - $1,182	230 New	230 $736,000
Q4 2021 Mar 21, 2023	BUY	$10.83 - $18.41 $2,707 - $4,602	250 Added 108.7%	480 $6.49 Million
Q3 2021 Mar 22, 2023	BUY	$13.07 - $18.84 $3,267 - $4,710	250 Added 108.7%	480 $8.62 Million
Q2 2021 Mar 22, 2023	BUY	$16.52 - $20.4 $826 - $1,019	50 Added 21.74%	280 $4.81 Million
Q1 2021 Mar 22, 2023	BUY	$16.56 - $25.46 $1,738 - $2,673	105 Added 45.65%	335 $6.7 Million
Q4 2020 Mar 22, 2023	BUY	$15.77 - $19.03 $1,655 - $1,998	105 Added 45.65%	335 $5.7 Million
Q3 2020 Mar 22, 2023	BUY	$16.59 - $24.79 $1,741 - $2,602	105 Added 45.65%	335 $5.56 Million
Q1 2020 Mar 24, 2023	BUY	$14.47 - $27.96 $7,307 - $14,119	505 Added 219.57%	735 $13.1 Million
Q4 2019 Mar 24, 2023	BUY	$15.87 - $23.12 $8,014 - $11,675	505 Added 219.57%	735 $15.9 Million
Q3 2019 Mar 24, 2023	BUY	$16.91 - $36.27 $3,382 - $7,254	200 Added 37.38%	735 $13.4 Million
Q2 2019 Mar 24, 2023	BUY	$31.0 - $36.3 $9,455 - $11,071	305 Added 132.61%	535 $19 Million
Q1 2019 Mar 24, 2023	SELL	$31.58 - $46.35 $1,421 - $2,085	-45 Reduced 8.57%	480 $16.1 Million
Q3 2018 Mar 24, 2023	BUY	$46.46 - $68.49 $13,705 - $20,204	295 Added 128.26%	525 $32 Million
Q2 2018 Mar 24, 2023	BUY	$46.25 - $104.45 $16,418 - $37,079	355 Added 154.35%	585 $28.6 Million

Others Institutions Holding NKTR

# of Institutions

140

Shares Held

135M

Call Options Held

32.8K

Put Options Held

55.5K

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.

Account

American Portfolios Advisors Nektar Therapeutics Transaction History